Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

9.580 +1.150 (+13.64%)

Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street ↗

June 13, 2024

Taking a small position in these penny stocks today could have you sitting on a sizable gain by the time Wall Street starts to pile in.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 11, 2024

Via Benzinga

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 07, 2024

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 14, 2024

From Gossamer Bio, Inc.

Via Business Wire

HC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know ↗

January 08, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 13, 2024

Via Benzinga

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2024

From Gossamer Bio, Inc.

Via Business Wire

GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 ↗

May 07, 2024

GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 07, 2024

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide ↗

May 06, 2024

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

Via Benzinga

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 06, 2024

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

May 03, 2024

From Gossamer Bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 25, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 05, 2024

Via Benzinga

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

March 12, 2024

From Gossamer Bio, Inc.

Via Business Wire

Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know ↗

March 06, 2024

Via Benzinga

GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 ↗

March 05, 2024

GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 05, 2024

From Gossamer Bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 20, 2024

Via Benzinga

7 Micro-Cap Stocks That Could Majorly Surprise Investors ↗

January 31, 2024

Although extremely small enterprises can be terrifyingly risky, these micro-cap stock surprises deserve a closer look.

Via InvestorPlace

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 08, 2024

From Gossamer Bio, Inc.

Via Business Wire

Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 18, 2023

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 18, 2023

Via Benzinga

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

December 13, 2023

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2023

From Gossamer Bio, Inc.

Via Business Wire

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

December 05, 2023

From Gossamer Bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

December 04, 2023

Via Benzinga

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

November 29, 2023

From Gossamer Bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 15, 2023

Via Benzinga

Gossamer Bio And 2 Other Stocks Under $1 Insiders Are Buying ↗

November 15, 2023

The Dow Jones closed higher by around 490 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.